Advertisement
Research ArticleArticle

Pharmacokinetics of Midazolam and 1′-Hydroxymidazolam in Chinese with Different CYP3A5 Genotypes

Pei-Shan Shih and Jin-Ding Huang
Drug Metabolism and Disposition December 2002, 30 (12) 1491-1496; DOI: https://doi.org/10.1124/dmd.30.12.1491

Abstract

The CYP3A subfamily represents the most abundant cytochrome P450 in the human liver and gastrointestinal tract and plays very important role in xenobiotic metabolism. CYP3A5 is expressed in a relatively small population of whites and Orientals. We recruited 42 Chinese volunteers to determine the genotypes of CYP3A5 by polymerase chain reaction-restriction fragment length polymorphism. Genotype analyses revealed thatCYP3A5*3 allele existed in 39 of 42 volunteers.CYP3A5*4 and CYP3A5*5 alleles were found in one volunteer each; and CYP3A5*2 andCYP3A5*6 alleles were not found. The most frequentCYP3A5*3 allele is known not to express CYP3A5. We excluded other genotypes of CYP3A5 to study the significance of CYP3A5*3 in midazolam pharmacokinetics. In this study, each volunteer was given a midazolam tablet (7.5 mg) orally. Blood samples were collected to analyze the time-dependent concentrations of midazolam and 1′-hydroxymidazolam by high-performance liquid chromatography. The average area under plasma concentration curve (AUC, 0–8 h) of midazolam was 9237 ± 1050 ng-min/ml (mean ± S.E.M.) in homozygous CYP3A5*3(n = 14) subjects and 7934 ± 768 ng-min/ml in heterozygous CYP3A5*1/*3 (n = 12) subjects, respectively. The average AUC (0–8 h) of 1′-hydroxymidazolam was 3748 ± 427 ng-min/ml in homozygous CYP3A5*3subjects and 3920 ± 402 ng-min/ml in heterozygousCYP3A5*1/*3 subjects. The results indicated that the pharmacokinetics of midazolam and 1′-hydroxymidazolam was independent of CYP3A5 expression. Although the genetic polymorphism of CYP3A5 is well known, the results of this study suggested that the clinical consequence might be insignificant.

Cytochrome P450s (P450)1are heme-containing monooxygenases and play an essential role in the oxidative biotransformation of endogenous compounds such as steroids, fatty acids, prostaglandins, and exogenous chemicals, including drugs, natural plant products, carcinogens, and environmental pollutants. CYP3A enzymes are the most abundantly expressed cytochrome P450 enzymes in liver (Hashimoto et al., 1993) and are responsible for the metabolism of over 50% of all clinically used drugs, including substances as diverse as steroids, antidepressants, benzodiazepines, immunosuppressive agents, midazolam, imidazole antimicotics, and macrolide antibiotics (Li et al., 1995; Paulussen et al., 2000).

In human, four members of the CYP3A subfamily, CYP3A4, CYP3A5, CYP3A7 (Nelson et al., 1996), and CYP3A43 (Domanski et al., 2001; Westlind et al., 2001), have been identified. The four CYP3A genes are localized in a cluster on chromosome 7q21-q22.1 (Spurr et al., 1989;Finta and Zaphiropoulos, 2000) and are characterized by a high structure similarity and protein sequence identity. The encoding genes have a well conserved exon-intron structure, all consisting of 13 exons (Hashimoto et al., 1993).

The predominant P450 form, CYP3A4, is a major P450 in the liver and intestine and has been reported to be involved in the metabolism of more than 60% of medically relevant drugs (Li et al., 1995). The expression of CYP3A5 is highly polymorphic and is estimated to comprise on average 7 to 8% of the total P450 content in human adult liver (Wrighton et al., 1989). It is also a major P450 in the kidney and intestine (Schuetz et al., 1992; Lin et al., 2002). CYP3A7 accounted for 30 to 50% of total P450 in fetal liver (Schuetz et al., 1994). CYP3A43 was identified recently (Domanski et al., 2001; Westlind et al., 2001). Overlapping substrate specificities between CYP3A4 and CYP3A5 have made it difficult to differentiate the two enzymes using probe drugs. The delineation of CYP3A4 and CYP3A5 metabolism has been shown to be possible only by using midazolam (Gorski et al., 1994;Haehner et al., 1996) or cyclosporine as a probe drug. Two metabolites of midazolam are formed: 1′OH-MDZ and 4-hydroxymidazolam. Wandel et al. (1994) quantified the hydroxylated metabolites by HPLC after incubation with P450 enzymes. They reported that CYP3A5 converted more MDZ to 1′OH-MDZ (127.4 ng/10 min/0.5 mg protein) than CYP3A4 did (26.8 ng/10 min/0.5 mg protein).

Immunoblotting and Northern blot analyses have detected CYP3A5 expression in only 10 to 30% of human livers (Aoyama et al., 1989;Wrighton et al., 1990; Schuetz et al., 1994). Another study showed that only 3% of human liver had detectable CYP3A5 by immunoblotting (Boobis et al., 1996). These findings suggested that CYP3A5 polymorphism might play an important role in functional regulation. The single nucleotide polymorphisms in CYP3A5*3 and CYP3A5*6 resulted in the absence of CYP3A5 in tissues (Kuehl et al., 2001). Among theCYP3A5*3 subjects, CYP3A5 expression comprises only 4.2% of total CYP3A in the liver and 2.7% of total CYP3A in the jejunum (Lin et al., 2002). However, among the heterozygous CYP3A5*1/*3subjects, CYP3A5 expression is appreciable, with 50% of total CYP3A in the liver and 61% of CYP3A in the jejunum. We report the results of CYP3A5 genotypes in 42 Chinese and of the pharmacokinetics of MDZ and 1′OH-MDZ in some Chinese subjects with different CYP3A5*3 genotypes after oral ingestion of MDZ (Wandel et al., 1998).

Materials and Methods

Human Subjects and DNA Isolation.

We recruited 42 healthy male subjects from the Chinese (Han) population living in Taiwan. Whole blood (10 ml) was obtained from each subject, and genomic DNA was isolated from peripheral leukocytes using the DNA isolation kit (Puregene; Gentra Systems, Inc., Minneapolis, MN).

PCR-RFLP for CYP3A5*2 in Intron 11.

A PCR-based test of CYP3A5*2 (T398N) was developed. To detect the C43196→A (GenBank no. AC005020.5) change, we used primer *2(S) and *2(R) to obtain a 363-bp PCR product (Table 1). The PCR reaction was carried out in 50 μl of solution consisting of reagents as listed in Table2. After PCR amplification, the DNA fragments were digested with Tsp509I before electrophoresis using 4% Nu-Sieve gel (Table 3). Samples with C43196 gave a 363-bp band, whereas samples with A43196 gave 239- and 124-bp bands. For other genotyping assay, the PCR-RFLP conditions used are shown in Tables 1(primer design), 2 (PCR conditions), and 3 (RFLP conditions), respectively.

View this table:
Table 1

Primers used to identify CYP3A5 variants

View this table:
Table 2

PCR conditions used in genotyping

View this table:
Table 3

RFLP conditions used in genotyping

PCR-RFLP for CYP3A5*3 in Intron 3.

A PCR-based test of CYP3A5*3 was developed. To detect the a22893→g change, at first we used primers pri-IN3(S) and IN3(R) to obtain a 310-bp PCR product. We also designed a mismatched primer IN3(S) to create the PstI restriction site (Table 2). Using IN3(S) and IN3(R), a nested PCR product of 166 bp was obtained and the resulting PCR product could be digested when there is g22893 mutation.

PCR-RFLP for CYP3A5*4, CYP3A5*5,CYP3A5*6, and CYP3AP1.

The PCR primers, PCR, and RFLP conditions for CYP3A5*4, CYP3A5*5, and CYP3AP1 are the same as described previously (Chou et al., 2001). A PCR-based test of CYP3A5*6was developed. To detect the A30597→G change, we used primer *6(S) and *6(R) to obtain a 141-bp PCR product. After PCR amplification, the DNA fragments were digested with DraI before electrophoresis using 4% Nu-Sieve gel. Sample with A30597 would have given a 141-bp band for the PCR product, whereas samples with G30597 gave 116- and 25-bp bands.

In Vivo MDZ Hydroxylation Assay.

Twenty-eight healthy male subjects were selected from the genotyping test for the pharmacokinetic study. The written consent of volunteers was obtained from each volunteer. The study was approved by the Ethics Committee of the Medical Center, National Cheng Kung University (Tainan, Taiwan). Each volunteer was given an MDZ tablet (7.5 mg, Dormicum; F. Hoffman-La Roche, Basel, Switzerland) orally. Blood samples, obtained at 10 different time points (0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, and 8 h), were collected to analyze the time-dependent concentrations of MDZ and 1′OH-MDZ concentrations by HPLC. Plasma samples were stored at −20°C until assay.

The plasma extraction procedure was carried out as described previously (Eeckhoudt et al., 1998). Midazolam and its metabolites were extracted with 3 ml of cyclohexane/diethyl ether (3:7) after the addition of 10 μl of 2% sodium hydroxide. The organic phase was removed and evaporated to dryness under nitrogen, and the residue was reconstituted in 200 μl of the mobile phase (methanol/10 mM phosphate buffer, pH 7.4/acetonitrile, 35:45:20). Ninety microliters of the mixture was injected for chromatographic analysis.

HPLC Analysis.

The HPLC system consisted of a 2690 separation module (Waters, Milford, MA), a 759A absorbance detector (Applied Biosystem, Ramsey, NJ), and an HP3395 integrator (Hewlett Packard, Avondale, PA). A Hypersil ODS column (5 μm particles, 4.6 mm i.d. × 250 mm; Thermo Hypersil Ltd., Cheshire, UK) was used. The separation of MDZ and the metabolites was achieved isocratically using the mobile phase (methanol/10 mM phosphate buffer, pH 7.4/acetonitrile, 35:45:20). The flow rate was 1.0 ml/min and the UV absorbance was monitored at 254 nm. All chromatographic separations were performed at room temperature.

Data Analysis.

The AUC (0–8 h) was calculated by the trapezoidal rule. The half-lives of MDZ and 1′OH-MDZ were determined by linear regression of data determined from samples obtained in the last three or four time points. The extrapolation of AUC was based on the last plasma concentration and the terminal slope (Cpn/λ). The ratio of 1′OH-MDZ/MDZ was also calculated to assess the CYP3A activity. The pharmacokinetic parameters were compared between two groups of subjects by two-tailed T test.

Results

We recruited 42 Chinese volunteers in Taiwan to determine the genotypes of CYP3A5 by PCR-RFLP. Genotype analyses revealed that the CYP3A5*3 allele was detected in 39 of 42 Chinese volunteers. CYP3A5*4 and CYP3A5*5 were found in one volunteer each; CYP3A5*2 andCYP3A5*6 were not found (Table4). For CYP3A5*3, the homozygous wild-type allele (*1/*1) was 7.1% (3 of 42), the heterozygous allele (*1/*3) was 40.5% (17 of 42), and the homozygous mutant-type allele (*3/*3) was 52.4% (22 of 42).

View this table:
Table 4

Genotypes and demographic data of the volunteers

To avoid the additive effect of other genotypes, we excluded subjects with genotypes of CYP3A5*4 and CYP4A5*5to study the significance of CYP3A5*3 in midazolam pharmacokinetics. The average AUC (0–8 h) of MDZ was 9237 ± 1050 ng-min/ml (mean ± S.E.M.) in homozygous CYP3A5*3(n = 14) subjects and 7934 ± 768 ng-min/ml in heterozygous CYP3A5*1/*3 (n = 12) subjects (Fig. 1). The two values are not significantly different (t = 0.97, P = 0.34). The average AUC (0–8 h) of 1′OH-MDZ was 3748 ± 427 ng-min/ml in homozygous CYP3A5*3 subjects and 3920 ± 402 ng-min/ml in heterozygous CYP3A5*1/*3 subjects (Fig. 1). The two values are also not significantly different (t= 0.29, P = 0.77). The AUC values were extrapolated and normalized by body weight. The AUC0-∞ values of MDZ and 1′-OH MDZ in CYP3A5*3 subjects are 235 ± 37.8 and 81.6 ± 10.1 ng-min/ml-kg, respectively; AUC0-∞ values of MDZ and 1′OH-MDZ inCYP3A5*1/*3 subjects are 215 ± 41.9 and 81.4 ± 13.6 ng-min/ml-kg, respectively. The values are not statistically different (t = 0.35, P = 0.72 for MDZ;t = 0.01, P = 0.99 for 1′OH-MDZ). The ratios of 1′OH-MDZ/MDZ are similar (0.54 ± 0.11 in homozygous CYP3A5*3 subjects and 0.48 ± 0.075 in heterozygous CYP3A5*1/*3 subjects; t = 0.22,P = 0.83). The two subjects of homozygousCYP3A5*1 allele (16 and 20) also showed similar pharmacokinetics of MDZ and 1′OH-MDZ (Fig. 1). The results showed that pharmacokinetics of MDZ and 1′OH-MDZ is of no difference in subjects with or without CYP3A5 expression.

Figure 1
Figure 1

Plasma drug concentration-time profiles after oral administration of midazolam. MDZ concentration profile is shown on left and 1′-OH MDZ concentration profile is shown on right.

The homozygous CYP3A5*3 alleles (●) and heterozygous CYP3A5*3 alleles (○) are shown. Each point represents the mean ± S.E.M. Subject no.16 with wild-type CYP3A5*1/*1 allele (▾) and subject no.20 with CYP3A5*1/*1 allele (▿) are shown.

Discussion

CYP3A5 is polymorphically expressed in 10 to 30% of human liver (Aoyama et al., 1989; Wrighton et al., 1990; Schuetz et al., 1994). It becomes clear that CYP3A5*3 is the most important allele responsible for the genetic polymorphism (Kuehl et al., 2001). The splicing variant, CYP3A5*3, forms the premature stop codon at amino acid 102, and therefore loses the enzyme activity.

In this study, the CYP3A5*3 allele with an a22893→g point mutation in the intron 3 of theCYP3A5 gene was examined by PCR-RFLP. We conclude that theCYP3A5*3 variant allele is abundantly present in the Chinese population, displaying an allelic frequency of 72.6%. For comparison,Hustert et al. (2001) reported that the CYP3A5*3 allele was detected in 73% of Chinese population, 71% of Japanese, 70% of Korean, and 27% of African American individuals. Fukuen et al. (2002)reported that the CYP3A5*3 allele was detected in 76.8% of Japanese population, 85.2% of Caucasian, and 47.5% of African American.

CYP3A5*4 and CYP3A5*5 (Chou et al., 2001) were found in 1 of 42 volunteers with an allelic frequency of 1.2% each, and CYP3A5*2 (Jounaidi et al., 1996) and CYP3A5*6(Kuehl et al., 2001) were not found in our study population (Table 4). In repeated experiments, we did not detect any CYP3A5*2variant in Chinese population (Chou et al., 2001). This is in contrast to the finding that there was 1.9% of CYP3A5*2 in Caucasian (Hustert et al., 2001). With respect to the absence ofCYP3A5*6 variant, the results of this study are identical to that in Japanese population (Fukuen et al., 2002). It seems that theCYP3A5*6 allelic frequency is also very low in the Oriental. Presently, the CYP3A5*4 and CYP3A5*5 allelic variants have only been found in the Chinese (Chou et al., 2001).

Kuehl et al. (2001) reported that individuals with a CYP3A5*1 allele had higher CYP3A5 protein expression and the metabolic activity than those with homozygous CYP3A5*3 allele as detected by the probe drug MDZ metabolism in vitro. In this study, the average AUC value of MDZ in homozygous CYP3A5*3 subjects was close to the value in heterozygous CYP3A5*1/*3 subjects. The average AUC value of 1′OH-MDZ was also very similar in the two groups. There were only two homozygous CYP3A5*1 subjects. Their MDZ and 1′OH-MDZ concentrations were also very similar to those of other subjects (Fig. 1). CYP3A5 expression level does not seem to be important in the pharmacokinetics of MDZ or 1′OH-MDZ. Recently, Yates et al. (2002) studied the effect of CYP3A5 genotypes in the disposition of cyclosporine. They found that the clearance of cyclosporine is the same in homozygous CYP3A5*3 and heterozygous CYP3A5*1/*3 subjects. The result was in agreement with that in the present study.

The ratio of 1′OH MDZ/MDZ AUCs was found to correlate with CYP3A activity well (Thummel et al., 1994a). In theory, the ratio reflects the formation clearance divided by the total elimination clearance of 1′OH-MDZ. We found average values of 0.51 for homozygousCYP3A5*3 subjects and 0.48 for heterozygousCYP3A5*1/*3 subjects. The values are not statistically different. Again, the results indicated that the rates of formation of 1′OH-MDZ are similar in the two genotypes of subjects.

It is interesting to find that the CYP3A5*3 genotype affects CYP3A5 level but does not affect MDZ pharmacokinetics in vivo. It is difficult to interpret the results. One possibility is that CYP3A5 is not the major enzyme in MDZ metabolism. There may be other enzymes responsible for converting MDZ into 1′OH-MDZ.

A recent report of tissue donors from Caucasians revealed that CYP3A5 protein was 70.7 pmol/mg in the liver and 3.6 pmol/mg in the jejunum for CYP3A5*1/*3 subjects, whereas CYP3A4 protein was 71.6 pmol/mg in the liver and 2.4 pmol/mg in the jejunum (Lin et al., 2002). The same report indicated that CYP3A5 was 2.5 pmol/mg in the liver and 0.5 pmol/mg in the jejunum for CYP3A5*3/*3 subjects, whereas CYP3A4 was 57.8 pmol/mg in the liver and 18.2 pmol/mg in the jejunum. In view of the activity ratio of 4.75 for CYP3A5/CYP3A4 in the conversion of MDZ to 1′OH-MDZ (Wandel et al., 1994), it can be estimated that CYP3A5*1/*3 liver has 5.8-fold activity compared with CYP3A5*3/*3 liver, and CYP3A5*1/*3 intestine has approximately the same 1′-hydroxylation activity as CYP3A5*3/*3 intestine. Because 1′-hydroxylation is the major metabolic pathway, approximately 5-fold difference can be expected that MDZ and 1′OH-MDZ plasma concentrations in the two groups of subjects with different CYP3A5 genotypes. The reason why midazolam and cyclosoporine level showed no difference in subjects of differentCYP3A5 genotypes cannot be explained by different expression level of CYP3A4 and CYP3A5 in the liver and the small intestine.

In previous studies, midazolam clearance after intravenous administration correlated better with hepatic CYP3A content (Thummel et al., 1994b) than the apparent oral midazolam clearance (Wandel et al., 1998). There is a possibility that the route of administration affects the phenotype difference in subjects of different genotypes. Lin et al. (2002) also showed that jejunal CYP3A4 up-regulated in homozygous CYP3A5*3 subjects. An intravenous midazolam study may give a larger metabolic activity difference between subjects of different CYP3A5 genotypes. The possibility remains to be elucidated.

The alternative hypothesis is that CYP3A genes are not regulated as expected. There is a possibility that CYP3A5*3 in Chinese subjects may have an increased expression of other functional proteins by unknown mechanism. Finta and Zaphiropoulos (2002) found that the intergenic mRNA molecules resulting from trans-splicing in CYP3A gene cluster. Even though only CYP3A43-CYP3A4 and CYP3A43-CYP3A5 chimeric protein were detected in very low percentage, CYP3A5*3 premRNA might have an alternative intergenic splicing to create an alternative functional protein in Chinese. The complicated chimericCYP3A mRNA levels and structures in the liver and the intestine need to be searched in the future to verify the hypothesis.

Furthermore, it is interesting to find that G/A−44 polymorphism of CYP3AP1promoter has strong association with a/g22893polymorphism in intron 3 of CYP3A5 in Chinese (Table 4). Other associated mutations might also exist to cause the compensation of enzymatic activity. Unidentified polymorphism in CYP3A4, CYP3A7, and CYP3A43 may exist in the population. The polymorphic sites may segregate with G/A−44 or a/g22893 site. The metabolic activity or expression of other members of CYP3A subfamily may have altered in CYP3A5*3 subjects.

MDZ and 1′OH-MDZ are both pharmacologically active. Even though the mechanism is unknown, the results suggest that CYP3A5 genotypes may not be an important factor in using MDZ. Other than MDZ and cyclosporine, importance of CYP3A5 in the metabolism of other CYP3A substrates needs to be investigated. Although CYP3A5 polymorphism is very interesting and widely observed, its clinical significance remains to be established.

Footnotes

  • The study was supported by the Grant DOH91-TD-1105 from Department of Health, Republic of China (Taiwan, Taipei).

  • Abbreviations used are::
    P450
    cytochrome P450
    1′OH-MDZ
    1′-hydroxymidazolam
    HPLC
    high-performance liquid chromatography
    MDZ
    midazolam
    PCR-RFLR
    polymerase chain reaction-restriction fragment length polymorphism
    PCR
    polymerase chain reaction
    bp
    base pair(s)
    AUC
    area under curve
    • Received July 1, 2002.
    • Accepted September 3, 2002.

References

  1. ↵
    1. Aoyama T,
    2. Yamano S,
    3. Waxman DJ,
    4. Lapenson DP,
    5. Meyer UA,
    6. Fischer V,
    7. Tyndale R,
    8. Inaba T,
    9. Kalow W,
    10. Gelboin HV
    (1989) Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. J Biol Chem 264:10388–10395.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Boobis AR,
    2. Edwards RJ,
    3. Adams DA,
    4. Davies DS
    (1996) Dissecting the function of cytochrome P450. Br J Clin Pharmacol 42:81–89.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Chou FC,
    2. Tzeng SJ,
    3. Huang JD
    (2001) Genetic polymorphism of cytochrome P450 3A5 in Chinese. Drug Metab Dispos 29:1205–1209.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Domanski TL,
    2. Finta C,
    3. Halpert JR,
    4. Zaphiropoulos PG
    (2001) cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450. Mol Pharmacol 59:386–392.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Eeckhoudt SL,
    2. Desager JP,
    3. Horsmans Y,
    4. De Winne AJ,
    5. Verbeeck RK
    (1998) Sensitive assay for midazolam and its metabolite 1′-hydroxymidazolam in human plasma by capillary high-performance liquid chromatography. J Chromatogr B 710:165–171.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Finta C,
    2. Zaphiropoulos PG
    (2000) The human cytochrome P450 3A locus. Gene evolution by capture of downstream exons. Gene 260:13–23.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Finta C,
    2. Zaphiropoulos PG
    (2002) Intergenic mRNA molecules resulting from trans-splicing. J Biol Chem 277:5882–5890.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Fukuen S,
    2. Fukuda T,
    3. Maune H,
    4. Ikenaga Y,
    5. Yamamoto I,
    6. Inaba T,
    7. Azuma J
    (2002) Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and *6, in a Japanese population. Pharmacogenetics 12:331–334.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Gorski JC,
    2. Hall SD,
    3. Jones DR,
    4. Vandenbranden M,
    5. Wrighton SA
    (1994) Regioselective biotransformation of midazolam by members of the human cytochrome P450 (CYP3A) subfamily. Biochem Pharmacol 47:1643–1653.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Haehner BD,
    2. Gorski JC,
    3. Vandenbranden M,
    4. Wrighton SA,
    5. Janardan SK,
    6. Watkins PB,
    7. Hall SD
    (1996) Bimodal distribution of renal cytochrome P450 3A activity in humans. Mol Pharmacol 50:52–59.
    OpenUrlAbstract
  11. ↵
    1. Hashimoto H,
    2. Toide K,
    3. Kitamura R,
    4. Fujita M,
    5. Tagawa S,
    6. Itoh S,
    7. Kamataki T
    (1993) Gene structure of CYP3A4, an adult-specific from of cytochrome P450 in human livers and its transcriptional control. Eur J Biochem 218:585–595.
    OpenUrlPubMed
  12. ↵
    1. Hustert E,
    2. Haberl M,
    3. Burk O,
    4. Wolbold R,
    5. He YQ,
    6. Klein K,
    7. Nuessler AC,
    8. Neuhaus P,
    9. Klattig J,
    10. Eiselt R,
    11. et al.
    (2001) The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 11:773–779.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Jounaidi Y,
    2. Hyrailles V,
    3. Gervot L,
    4. Maurel P
    (1996) Detection of CYP3A5 allelic variant: a candidate for the polymorphic expression of the protein? Biochem Biophys Res Commun 221:466–470.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Kuehl P,
    2. Zhang J,
    3. Lin Y,
    4. Lamba J,
    5. Assem M,
    6. Schuetz J,
    7. Watkins PB,
    8. Daly A,
    9. Wrighton SA,
    10. Hall SD,
    11. et al.
    (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383–391.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Li AP,
    2. Kaminski DL,
    3. Rasmussen A
    (1995) Substrates of human hepatic cytochrome P450 3A4. Toxicology 104:1–8.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Lin YS,
    2. Dowling ALS,
    3. Quigley SD,
    4. Farin FM,
    5. Zhang J,
    6. Lamba J,
    7. Schuetz EG,
    8. Thummel KE
    (2002) Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 62:162–172.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. Nelson DR,
    2. Koymans L,
    3. Kamataki T,
    4. Stegeman JJ,
    5. Feyereisen R,
    6. Waxman DJ,
    7. Waterman MR,
    8. Gotoh O,
    9. Coon MJ,
    10. Estabrook RW,
    11. et al.
    (1996) P450 superfamily: update on new sequences, gene mapping, accession Nos and nomenclature. Pharmacogenetics 6:1–42.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Paulussen A,
    2. Lavrijsen K,
    3. Bohets H,
    4. Hendrickx J,
    5. Verhasselt P,
    6. Luyten W,
    7. Konings F,
    8. Armstrong M
    (2000) Two linked mutations in transcriptional regulatory elements of the CYP3A5 gene constitute the major genetic determinant of polymorphic activity in humans. Pharmacogenetics 10:415–424.
    OpenUrlCrossRefPubMed
  19. ↵
    1. Schuetz JD,
    2. Beach DL,
    3. Guzelian PS
    (1994) Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver. Pharmacogenetics 4:11–20.
    OpenUrlCrossRefPubMed
  20. ↵
    1. Schuetz EG,
    2. Schuetz JD,
    3. Mclean Grogan WM,
    4. Naray-Fejes-Toth A,
    5. Fejes-Toth G,
    6. Raucy J,
    7. Guzelian P,
    8. Gionela K,
    9. Watlington CO
    (1992) Expression of cytochrome P450 3A in amphibian, rat and human kidney. Arch Biochem Biophys 294:206–214.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Spurr NK,
    2. Gough AC,
    3. Stevenson K,
    4. Wolf CR
    (1989) The human cytochrome P450 CYP3A locus: assignment to chromosome 7q22-qter. Hum Genet 81:171–174.
    OpenUrlCrossRefPubMed
  22. ↵
    1. Thummel KE,
    2. Shen DD,
    3. Podoll TD,
    4. Kunze KL,
    5. Trager WF,
    6. Bacchi CE,
    7. Marsh CL,
    8. McVicar JP,
    9. Barr DM,
    10. Perkins JD
    (1994a) Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation. J Pharamcol Exp Ther 271:557–566.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Thummel KE,
    2. Shen DD,
    3. Podoll TD,
    4. Kunze KL,
    5. Trager WF,
    6. Hartwell PS,
    7. Raisys VA,
    8. Marsh CL,
    9. McVicar JP,
    10. Barr DM
    (1994b) Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. J Pharamcol Exp Ther 271:549–556.
    OpenUrlAbstract/FREE Full Text
  24. ↵
    1. Wandel C,
    2. Böcker RH,
    3. Böhrer H,
    4. Browne A,
    5. Rugheimer E,
    6. Martin E
    (1994) Midazolam is metabolized by at least three different cytochrome P450 enzymes. Br J Anaesth 73:658–661.
    OpenUrlAbstract/FREE Full Text
  25. ↵
    1. Wandel C,
    2. Böcker RH,
    3. Böhrer H,
    4. deVries JX,
    5. Hofmann W,
    6. Walter K,
    7. Kleingeist B,
    8. Neff S,
    9. Ding R,
    10. Water-Sack I,
    11. Martin E
    (1998) Relationship between hepatic cytochrome P450 3A content and activity and the disposition of midazolam administered orally. Drug Metab Dispos 26:110–114.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    1. Westlind A,
    2. Malmebo S,
    3. Johansson I,
    4. Otter C,
    5. Andersson TB,
    6. Ingelman-Sundberg M,
    7. Oscarson M
    (2001) Cloning and tissue distribution of a novel human cytochrome P450 of the CYP3A subfamily, CYP3A43. Biochem Biophys Res Commun 281:1349–1355.
    OpenUrlCrossRefPubMed
  27. ↵
    1. Wrighton SA,
    2. Brian WR,
    3. Sari MA,
    4. Iwasaki M,
    5. Guengerich FP
    (1990) Studies on the expression and metabolic capabilities of human liver cytochrome P-450 A5 (HLp3). Mol Pharmacol 38:207–213.
    OpenUrlAbstract
  28. ↵
    1. Wrighton SA,
    2. Ring BJ,
    3. Watkins PB,
    4. Vandenbranden M
    (1989) Identification of a polymorphism expressed member of the human cytochrome P-450 family. Mol Pharmacol 36:97–105.
    OpenUrlAbstract
  29. ↵
    1. Yates CR,
    2. Zhang W,
    3. Song P,
    4. Gaber AO,
    5. Honaker MR,
    6. Kotb M,
    7. Alloway RR,
    8. Meibohm DB
    (2002) Effect of CYP3A5 genotype on cyclosporine disposition: a pilot study. Clin Pharmacol Ther 71:P2.
    OpenUrl
View Abstract

 

DMD articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

 

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools
Research ArticleArticle

Pharmacokinetics of Midazolam and 1′-Hydroxymidazolam in Chinese with Different CYP3A5 Genotypes

Pei-Shan Shih and Jin-Ding Huang
Drug Metabolism and Disposition December 1, 2002, 30 (12) 1491-1496; DOI: https://doi.org/10.1124/dmd.30.12.1491
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Jump to section